Article | October 1, 2016

Comprehensive Solutions For Aggregate Issues

Comprehensive Solutions For Aggregate Issues

The success of any biologic, such as monoclonal antibodies (mAbs), recombinant proteins, or biosimilars, depends greatly on downstream molecule purification. Process scientists often face multiple challenges during this process, including the formation of aggregates. Aggregate molecules are essentially multimers of the monomers. Although they are mostly physically and chemically similar to monomers, their presence in the final purified product, especially a therapeutic mAb, is undesirable due to multiple reasons. First, aggregate formation can lead to a domino effect wherein other impurities like host cell proteins (HCPs) and DNA can bind to the multimers leading to the formation of complex contaminants.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: